{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:55:10Z","timestamp":1761947710835,"version":"build-2065373602"},"reference-count":83,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.revmed.2010.11.007","type":"journal-article","created":{"date-parts":[[2011,3,7]],"date-time":"2011-03-07T17:24:21Z","timestamp":1299518661000},"page":"494-505","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Guide de recommandations d\u2019utilisation des bisphosphonates dans les l\u00e9sions osseuses malignes des tumeurs solides et du my\u00e9lome multiple"],"prefix":"10.1016","volume":"32","author":[{"given":"J.-F.","family":"Brantus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Roemer-Becuwe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Cony-Makhoul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Salino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Debourdeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-P.","family":"Guastalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Ghesquieres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Sebban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Pavic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Collet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-P.","family":"Larbre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Martinon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Brocard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.-G.","family":"Bodard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Balestri\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Favier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Farsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Krakowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Biron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2010.11.007_bib0005","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.revmed.2010.11.007_bib0010","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ctrv.2008.05.001","article-title":"Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions","volume":"34","author":"Coleman","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.revmed.2010.11.007_bib0015","first-page":"9","article-title":"Pathophysiologie des m\u00e9tastases osseuses","volume":"13","author":"Chappard","year":"2003","journal-title":"Prog Urol"},{"issue":"Suppl. 12","key":"10.1016\/j.revmed.2010.11.007_bib0020","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1002\/1097-0142(20000615)88:12+<3054::AID-CNCR23>3.0.CO;2-Z","article-title":"Current and future directions in medical therapy: hypercalcemia","volume":"88","author":"Body","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.revmed.2010.11.007_bib0025","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.semnephrol.2003.08.015","article-title":"Hypercalcemia of malignancy","volume":"24","author":"Body","year":"2004","journal-title":"Semin Nephro"},{"key":"10.1016\/j.revmed.2010.11.007_bib0030","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.eururo.2004.08.016","article-title":"Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care","volume":"46","author":"Saad","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.revmed.2010.11.007_bib0035","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/01.mlr.0000108746.69256.45","article-title":"Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions","volume":"42","author":"Weinfurt","year":"2004","journal-title":"Med Care"},{"key":"10.1016\/j.revmed.2010.11.007_bib0040","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.revmed.2010.11.007_bib0045","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1090-3801(02)00028-9","article-title":"Palliative radiotherapy in the treatment of skeletal metastases","volume":"6","author":"Saarto","year":"2002","journal-title":"Eur J Pain"},{"key":"10.1016\/j.revmed.2010.11.007_bib0050","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/annonc\/mdi162","article-title":"Bisphosphonates in breast cancer","volume":"16","author":"Coleman","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.revmed.2010.11.007_bib0055","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3816\/SCT.2007.n.003","article-title":"Treatment of bone metastases and bone pain with bisphosphonates","volume":"4","author":"Lipton","year":"2007","journal-title":"Support Cancer Ther"},{"key":"10.1016\/j.revmed.2010.11.007_bib0060","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1159\/000082923","article-title":"The cost of treatment of skeletal related events in patients with bone metastases from lung cancer","volume":"67","author":"Delea","year":"2004","journal-title":"Oncology"},{"key":"10.1016\/j.revmed.2010.11.007_bib0065","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.revmed.2010.11.007_bib0070","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/bcr414","article-title":"Development of bisphosphonates","volume":"4","author":"Fleisch","year":"2002","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.revmed.2010.11.007_bib0075","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1002\/jbmr.5650091206","article-title":"Structural requirements for bisphosphonates actions in vitro","volume":"12","author":"Van Beek","year":"1994","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.revmed.2010.11.007_bib0080","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.2174\/1381612033453640","article-title":"New insights into the molecular mechanisms of action of bisphosphonates","volume":"9","author":"Rogers","year":"2003","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.revmed.2010.11.007_bib0085","first-page":"233","article-title":"Mechanisms of action of etidronate and other bisphosphonates","volume":"9","author":"Ebetino","year":"1998","journal-title":"Rev Contemp Pharmacother"},{"key":"10.1016\/j.revmed.2010.11.007_bib0090","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1196\/annals.1402.089","article-title":"Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy","volume":"1117","author":"Russell","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.revmed.2010.11.007_bib0095","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1054\/bjoc.2000.1679","article-title":"Bisphosphonates regulate cell growth and gene expression in the UMR 106-01\u00a0clonal rat osteosarcoma cell line","volume":"84","author":"Mackie","year":"2001","journal-title":"Brit J Cancer"},{"key":"10.1016\/j.revmed.2010.11.007_bib0100","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1006\/bbrc.2002.6510","article-title":"Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts","volume":"291","author":"Viereck","year":"2002","journal-title":"Biochem Biophys Res Comm"},{"key":"10.1016\/j.revmed.2010.11.007_bib0105","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","article-title":"American Society of Clinical Oncology Bisphosphonates Expert Panel. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma","volume":"20","author":"Berenson","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2010.11.007_bib0110","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003\u00a0update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2010.11.007_bib0115","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4065\/81.8.1047","article-title":"Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma","volume":"81","author":"Lacy","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.revmed.2010.11.007_bib0120","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","article-title":"American Society of Clinical Oncology 2007\u00a0clinical practice guideline update on the role of bisphosphonates in multiple myeloma","volume":"25","author":"Kyle","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2010.11.007_bib0125","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.revmed.2010.11.007_bib0130","unstructured":"R\u00e9seau R\u00e9gional de Canc\u00e9rologie Rh\u00f4ne-Alpes. Adresse internet: www.rrc-ra.fr."},{"key":"10.1016\/j.revmed.2010.11.007_bib0135","unstructured":"The NCCN Breast Cancer Clinical Practice Guidelines in Oncology (version 2.2008). 2008\u00a0National Comprehensive Cancer Network, Inc\u00a9. Adresse internet: http:\/\/www.nccn.org."},{"key":"10.1016\/j.revmed.2010.11.007_bib0140","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.revmed.2010.11.007_bib0145","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"10.1016\/j.revmed.2010.11.007_bib0150","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomised, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.revmed.2010.11.007_bib0155","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.revmed.2010.11.007_bib0160","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","article-title":"Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies","volume":"90","author":"Body","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.revmed.2010.11.007_bib0165","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2010.11.007_bib0170","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.revmed.2010.11.007_bib0175","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.revmed.2010.11.007_bib0180","first-page":"539","article-title":"Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer","volume":"16","author":"Heras","year":"2007","journal-title":"Eur J Cancer Care"},{"key":"10.1016\/j.revmed.2010.11.007_bib0185","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1200\/JCO.2006.05.9212","article-title":"Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy","volume":"24","author":"Clemons","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2010.11.007_bib0190","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10549-007-9583-y","article-title":"A phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal-related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonates (BP) therapy","volume":"108","author":"Clemons","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.revmed.2010.11.007_bib0195","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2010.11.007_bib0200","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2796.1999.00507.x","article-title":"Oral clodronate in breast cancer patients with bone metastases: a randomized study","volume":"246","author":"Kristensen","year":"1999","journal-title":"J Intern Med"},{"key":"10.1016\/j.revmed.2010.11.007_bib0205","first-page":"CD003474","article-title":"Bisphosphonates for breast cancer","volume":"20","author":"Pavlakis","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.revmed.2010.11.007_bib0210","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1600-0773.1996.tb00260.x","article-title":"Effect of concomitant administration of clodronate and extramustine phosphate on their bioavailability in patients with metastasized prostate cancer","volume":"79","author":"Kylm\u00e4l\u00e4","year":"1996","journal-title":"Pharmacol Toxicol"},{"key":"10.1016\/j.revmed.2010.11.007_bib0215","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1200\/JCO.2003.05.147","article-title":"Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer","volume":"21","author":"Small","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2010.11.007_bib0220","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/jnci\/djg038","article-title":"A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PRO5\u00a0trial)","volume":"95","author":"Dearnaley","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"5\u00a0Suppl. 10","key":"10.1016\/j.revmed.2010.11.007_bib0225","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.seminoncol.2004.07.026","article-title":"Ibandronate in metastatic bone pain","volume":"31","author":"Heidenreich","year":"2004","journal-title":"Semin Oncol"},{"key":"10.1016\/j.revmed.2010.11.007_bib0230","doi-asserted-by":"crossref","unstructured":"Saad F, Gleason DM, Murray R, et al. Zoledronic acid reduces skeletal morbidity regardless of previous skeletal events in men with prostate cancer and bone metastases [poster]. Paris, France: Presented at: 21st Annual Congress of the European Association of Urology 2006\u00a0April 5\u20138 (Abstract 141).","DOI":"10.1016\/S1569-9056(06)60148-6"},{"key":"10.1016\/j.revmed.2010.11.007_bib0235","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s11912-006-0023-7","article-title":"The role of bisphosphonates in the management of prostate cancer","volume":"8","author":"Saad","year":"2006","journal-title":"Curr Oncol Rep."},{"key":"10.1016\/j.revmed.2010.11.007_bib0240","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial \u2013 the Zoledronic Acid Lung Cancer and Other solid Tumors study group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2010.11.007_bib0245","first-page":"213","article-title":"A double-blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy","volume":"17","author":"Piga","year":"1998","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.revmed.2010.11.007_bib0250","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2010.11.007_bib0255","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group","volume":"16","author":"Berenson","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2010.11.007_bib0260","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.2002.02.032","article-title":"Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patient with advanced multiple myeloma","volume":"20","author":"Menssen","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2010.11.007_bib0265","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","article-title":"A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma","volume":"100","author":"McCloskey","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2010.11.007_bib0270","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1365-2141.2001.02851.x","article-title":"Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma","volume":"113","author":"McCloskey","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2010.11.007_bib0275","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.3109\/10428190309178778","article-title":"Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial","volume":"44","author":"Musto","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.revmed.2010.11.007_bib0280","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in multiple myeloma patients","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2010.11.007_bib0285","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jpainsymman.2007.01.001","article-title":"Managing metastatic bone pain: the role of bisphosphonates","volume":"33","author":"Gralow","year":"2007","journal-title":"J Pain Symptom Manage"},{"issue":"4\u00a0Suppl. 1","key":"10.1016\/j.revmed.2010.11.007_bib0290","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.amjmed.2005.12.019","article-title":"Improving compliance and persistence with bisphosphonate therapy for osteoporosis","volume":"119","author":"Emkey","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.revmed.2010.11.007_bib0295","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/cncr.23775","article-title":"Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database","volume":"113","author":"Hatoum","year":"2008","journal-title":"Cancer."},{"key":"10.1016\/j.revmed.2010.11.007_bib0300","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00198-009-0871-8","article-title":"Comparative gastrointestinal safety of weekly oral bisphosphonates","volume":"20","author":"Cadarette","year":"2009","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.revmed.2010.11.007_bib0305","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00198-006-0322-8","article-title":"A systematic review of persistence and compliance with bisphosphonates for osteoporosis","volume":"18","author":"Cramer","year":"2007","journal-title":"Osteoporosis Int"},{"key":"10.1016\/j.revmed.2010.11.007_bib0310","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1185\/030079906X154042","article-title":"Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate","volume":"22","author":"Gold","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.revmed.2010.11.007_bib0315","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.breast.2008.02.009","article-title":"Which bisphosphonates do oncologists prescribe for women with metastatic breast cancer and why? Results of a UK survey","volume":"17","author":"Fallowfield","year":"2008","journal-title":"Breast."},{"key":"10.1016\/j.revmed.2010.11.007_bib0320","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/ncponc0688","article-title":"Therapy Insight: the risks and benefits of bisphosphonates for treatment of tumor-induced bone disease","volume":"4","author":"Dunstan","year":"2007","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.revmed.2010.11.007_bib0325","doi-asserted-by":"crossref","first-page":"96","DOI":"10.14310\/horm.2002.1226","article-title":"Bisphosphonate-associated adverse events","volume":"8","author":"Papapetrou","year":"2009","journal-title":"Hormones (Athens)"},{"key":"10.1016\/j.revmed.2010.11.007_bib0330","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2249.2005.02665.x","article-title":"The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates in inhibited by statins","volume":"139","author":"Hewitt","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.revmed.2010.11.007_bib0335","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1517\/14740338.5.4.585","article-title":"Drug-induced side effects affecting the gastrointestinal tract","volume":"5","author":"Leong","year":"2006","journal-title":"Expert Opin Drug Saf"},{"issue":"Suppl. 1","key":"10.1016\/j.revmed.2010.11.007_bib0340","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1634\/theoncologist.10-90001-19","article-title":"Bisphosphonate treatment recommendations for oncologist","volume":"10","author":"Von Moos","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.revmed.2010.11.007_bib0345","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1634\/theoncologist.10-5-306","article-title":"The issue of renal safety of zoledronic acid from a nephrologist's point of view","volume":"10","author":"Balla","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.revmed.2010.11.007_bib0350","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.revmed.2008.12.013","article-title":"Une ost\u00e9on\u00e9crose de la m\u00e2choire","volume":"30","author":"Pierrot-Deseilligny-Despujol","year":"2009","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2010.11.007_bib0355","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"(Aredia) and zol\u00e9dronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.revmed.2010.11.007_bib0360","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.revmed.2010.11.007_bib0365","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2010.11.007_bib0370","first-page":"968","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid","volume":"91","author":"Dimopoulos","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.revmed.2010.11.007_bib0375","unstructured":"Afssaps. Recommandations sur la prise en charge bucco-dentaire des patients trait\u00e9s par bisphosphonates 18\u00a0d\u00e9cembre 2007. Ref Type: Generic. http:\/\/www.afssaps.fr\/Infos-de-securite\/Lettres-aux-professionnels-de-sante\/Recommandations-sur-la-prise-en-charge-bucco-dentaire-des-patients-traites-par-bisphosphonates\/(language)\/fre-FR."},{"key":"10.1016\/j.revmed.2010.11.007_bib0380","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1051\/mbcb\/2008015","article-title":"Ost\u00e9on\u00e9crose des maxillaires due aux bisphosphonates\u00a0: mise au point","volume":"14","author":"Abi Najm","year":"2008","journal-title":"Med Buccal Chir Buccal"},{"key":"10.1016\/j.revmed.2010.11.007_bib0385","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.revmed.2009.02.007","article-title":"Ost\u00e9on\u00e9crose mandibulaire et bisphosphonates\u00a0: \u00e9tat actuel et perspectives","volume":"30","author":"Gligorov","year":"2009","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2010.11.007_bib0390","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1182\/blood-2006-07-033571","article-title":"Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone","volume":"108","author":"Tosi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2010.11.007_bib0395","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.oraloncology.2007.11.012","article-title":"Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80\u00a0patients with multiple myeloma and other malignancies","volume":"44","author":"Boonyapakorn","year":"2008","journal-title":"Oral Oncol"},{"key":"10.1016\/j.revmed.2010.11.007_bib0400","first-page":"1322","article-title":"Management of complications of bisphosphonates in oncology patients: jaw osteonecrosis","volume":"3","author":"Madrid","year":"2007","journal-title":"Rev Med Suisse"},{"key":"10.1016\/j.revmed.2010.11.007_bib0405","first-page":"36","article-title":"Osteonecrosis of the jaw after treatment with bisphosphonates is irreversible, so the focus must be on prevention","volume":"14","author":"Landis","year":"2007","journal-title":"Prim Dent Care"},{"key":"10.1016\/j.revmed.2010.11.007_bib0410","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/annonc\/mdn526","article-title":"Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan","volume":"20","author":"Ripamonti","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.revmed.2010.11.007_bib0415","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.critrevonc.2006.12.005","article-title":"Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients \u2013 May 2006","volume":"62","author":"Weitzman","year":"2007","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866311000397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866311000397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:28:12Z","timestamp":1759336092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866311000397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":83,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0248866311000397"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2010.11.007","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2011,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guide de recommandations d\u2019utilisation des bisphosphonates dans les l\u00e9sions osseuses malignes des tumeurs solides et du my\u00e9lome multiple","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2010.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Soci\u00e9t\u00e9 nationale fran\u00e7aise de m\u00e9decine interne (SNFMI). Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}